Women's health biotech nabs new antimicrobial treatment; Ovid finds partner for neuroscience collaboration
Daré Bioscience is on the move.
The biotech put out word early Wednesday morning that it’s signed a licensing agreement with Hennepin Life Sciences. Daré now has exclusive global rights to develop and commercialize treatments delivering glycerol monolaurate, or GML. GML is a new antimicrobial for a variety of vaginal health conditions — including bacterial, fungal and viral infections.
The biotech claims that due to its mechanism of action, there is “little chance” of antibiotic resistance as a result of this drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.